Alliance pharmaceutique pancanadienne (APP) – dernières mises à jour
| État | Nombre total | Résumé |
|---|---|---|
| En négociation | 47 | Non liées à l’oncologie : 31 Liées à l’oncologie : 16 |
| Négociations envisagées | 18 | Non liées à l’oncologie : 11 Liées à l’oncologie : 7 |
| Négociations terminées | 918 | Avec lettre d’intention : 792 Sans entente : 126 |
| Négociations qui n’ont pas eu lieu | 113 |
Activités de l’APP dans les quatre dernières semaines
Voici les activités des quatre dernières semaines. Veuillez prendre note que le traitement de ces mises à jour peut prendre d’une à deux semaines.
Lettres d’engagement transmises au cours des quatre dernières semaines
| Marque | Fabricant | Indication | Date d’engagement |
|---|---|---|---|
| Conexxence | Fresenius Kabi Canada Ltd. | • treatment of postmenopausal women with osteoporosis at high risk for fracture; • treatment to increase bone mass in men with osteoporosis at high risk for fracture; • treatment to increase bone mass in men with nonmetastatic prostate cancer receiving an | |
| Bomyntra | Fresenius Kabi Canada Ltd. | • reducing the risk of developing skeletal-related events in patients with multiple myeloma and in patients with bone metastases from breast cancer, prostate cancer, non-small cell lung cancer, and other solid tumors; • treatment of adults and skeletally | |
| Blenrep (belantamab mafodotin) | GlaxoSmithKline Inc. | For the treatment of multiple myeloma in combination with pomalidomide and dexamethasone (Bpd) in adult patients who have received at least one prior therapy including lenalidomide. | |
| Dupixent | Sanofi Genzyme Canada | Indicated as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils inadequately controlled by the combination of an inhaled corticosteroid (ICS), a long-acting beta2-a | |
| Blenrep (belantamab mafodotin) | GlaxoSmithKline Inc. | For the treatment of multiple myeloma in combination with bortezomib and dexamethasone (BVd) in adult patients who have received at least one prior therapy. | |
| Yondelis | Xediton Pharmaceuticals Inc | in combination with doxorubicin as first-line treatment for advanced unresectable or metastatic uterine or soft tissue leiomyosarcoma | |
| Enhertu | AstraZeneca Canada Inc. | Advanced or Metastatic Gastric Cancer or Gastro-esophageal Junction (GEJ) Adenocarcinoma |